美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Polaryx Therapeutics Inc

2.00

-0.0700-3.38%

成交量：3.48萬

成交額：7.06萬

市值：9,969.20萬

市盈率：-14.60

高：2.10

開：2.08

低：1.99

收：2.07

52周最高：48.91

52周最低：1.86

股本：4,984.60萬

流通股本：677.78萬

量比：2.24

換手率：0.51%

股息：- -

股息率：- -

每股收益(TTM):-0.1370

每股收益(LYR):-0.1978

淨資產收益率：-96.56%

總資產收益率：-42.52%

市淨率：9.11

市盈率(LYR):-10.11

資料載入中...

總覽公司新聞資訊公告

H.C. Wainwright首次覆蓋Polaryx Therapeutics，給予買入評級，目標價7美元

Polaryx Therapeutics完成1000萬美元私募股權融資，以支持啓動Soteria二期籃子試驗

BUZZ-美國食品和藥物管理局授予罕見病藥物快速通道資格後，Polaryx 股價上漲

Polaryx Therapeutics四款適應症均獲美國FDA快速通道資格，將納入Soteria籃子試驗評估

Polaryx Therapeutics獲FDA快速通道資格，Plx-200治療晚嬰期神經元蠟樣脂褐質沉積症（CLN2病）

Polaryx Therapeutics獲FDA安全許可函，將於2026年第三季度啓動Soteria試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/PLYX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLYX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","market":"US","secType":"STK","nameCN":"Polaryx Therapeutics Inc","latestPrice":2,"timestamp":1787580836743,"preClose":2.07,"halted":0,"volume":34831,"delay":0,"changeRate":-0.033816425120772875,"floatShares":6777800,"shares":49846000,"eps":-0.137,"marketStatus":"交易中","change":-0.07,"latestTime":"08-24 10:16:13 EDT","open":2.08,"high":2.1028,"low":1.99,"amount":70647.7033676,"amplitude":0.054493,"askPrice":2.02,"askSize":180,"bidPrice":2,"bidSize":234,"shortable":3,"etf":0,"ttmEps":-0.137,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1769749200000,"exchange":"NASDAQ","adjPreClose":2.07,"preHourTrading":{"tag":"盘前","latestPrice":2.0604,"preClose":2.07,"latestTime":"08:54 EDT","volume":5038,"amount":10505.376144999998,"timestamp":1787576057151,"change":-0.0096,"changeRate":-0.004638,"amplitude":0.028309},"postHourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.07,"latestTime":"19:53 EDT","volume":64,"amount":132.5006,"timestamp":1787356396629,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.239625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","floatShares":6777800,"roa":"-42.52%","roe":"-96.56%","lyrEps":-0.197809,"volumeRatio":2.239625,"shares":49846000,"dividePrice":0,"high":2.1028,"amplitude":0.054493,"preClose":2.07,"low":1.99,"week52Low":1.86,"pbRate":"9.11","week52High":48.91,"institutionHeld":0,"latestPrice":2,"committee":0.130435,"eps":-0.137,"divideRate":0,"volume":34831,"delay":0,"ttmEps":-0.137,"open":2.08,"prevYearClose":45,"prevWeekClose":2.07,"prevMonthClose":2.31,"prevQuarterClose":2.66,"fiveDayClose":2.1,"twentyDayClose":1.96,"sixtyDayClose":3.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLYX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"PLYX","fiscalQuarterEnding":"2026/06","expectedEps":-0.05,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLYX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1786680000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLYX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLYX","date":"2026-08-21","current":-15.109489,"percent":0.913669,"low":-201.755192,"twenty":-31.888849,"median":-18.858377,"eighty":-16.490115,"high":-13.892286,"avg":-26.119255,"sd":21.979805,"marketCap":106670425},"quantilePoints":[{"date":"2026-01-30","current":-58.797227,"twenty":-58.797227,"median":-58.797227,"eighty":-58.797227,"marketCap":482901629},{"date":"2026-02-06","current":-92.230945,"twenty":-129.699766,"median":-109.380137,"eighty":-58.797227,"marketCap":757492752},{"date":"2026-02-13","current":-16.832147,"twenty":-126.529328,"median":-58.797227,"eighty":-25.939953,"marketCap":138242427},{"date":"2026-02-20","current":-15.391039,"twenty":-99.090622,"median":-34.183094,"eighty":-16.79756,"marketCap":126406602},{"date":"2026-02-27","current":-18.388545,"twenty":-65.483971,"median":-21.847205,"eighty":-15.852193,"marketCap":151025117},{"date":"2026-03-06","current":-15.102817,"twenty":-58.797227,"median":-17.581524,"eighty":-15.852193,"marketCap":124039438},{"date":"2026-03-13","current":-26.804618,"twenty":-52.848332,"median":-19.339676,"eighty":-15.932895,"marketCap":220146331},{"date":"2026-03-20","current":-32.569052,"twenty":-39.601662,"median":-22.827159,"eighty":-16.059713,"marketCap":267489628},{"date":"2026-03-27","current":-33.617166,"twenty":-34.863297,"median":-29.312147,"eighty":-16.128886,"marketCap":302050234},{"date":"2026-04-02","current":-40.045527,"twenty":-39.919067,"median":-31.906143,"eighty":-16.140415,"marketCap":359809057},{"date":"2026-04-10","current":-30.350294,"twenty":-38.506935,"median":-31.819676,"eighty":-16.417108,"marketCap":272697390},{"date":"2026-04-17","current":-33.669857,"twenty":-37.045768,"median":-31.906143,"eighty":-16.636156,"marketCap":302523667},{"date":"2026-04-24","current":-28.031869,"twenty":-35.562162,"median":-31.819676,"eighty":-16.762974,"marketCap":251866340},{"date":"2026-05-01","current":-27.663028,"twenty":-34.579831,"median":-30.218565,"eighty":-17.281773,"marketCap":248552309},{"date":"2026-05-08","current":-20.128146,"twenty":-34.275325,"median":-29.928762,"eighty":-18.065737,"marketCap":180851394},{"date":"2026-05-15","current":-17.967795,"twenty":-34.128071,"median":-28.532438,"eighty":-17.67102,"marketCap":161440642},{"date":"2026-05-22","current":-28.799226,"twenty":-34.059774,"median":-27.768411,"eighty":-17.809721,"marketCap":186532590},{"date":"2026-05-29","current":-22.293817,"twenty":-33.996545,"median":-27.504954,"eighty":-17.904565,"marketCap":144397055},{"date":"2026-06-05","current":-18.492904,"twenty":-33.827932,"median":-26.891329,"eighty":-18.119363,"marketCap":119778541},{"date":"2026-06-12","current":-17.396487,"twenty":-33.648781,"median":-26.314014,"eighty":-17.641188,"marketCap":112677046},{"date":"2026-06-18","current":-16.884826,"twenty":-33.534361,"median":-25.713443,"eighty":-17.290923,"marketCap":109363016},{"date":"2026-06-26","current":-16.884826,"twenty":-33.180562,"median":-24.313934,"eighty":-17.139848,"marketCap":109363016},{"date":"2026-07-02","current":-18.858377,"twenty":-33.090251,"median":-23.364528,"eighty":-17.282806,"marketCap":122145706},{"date":"2026-07-10","current":-17.761959,"twenty":-32.741985,"median":-22.293817,"eighty":-17.323392,"marketCap":115044211},{"date":"2026-07-17","current":-16.884826,"twenty":-32.569052,"median":-20.503003,"eighty":-17.031015,"marketCap":109363016},{"date":"2026-07-24","current":-15.422936,"twenty":-32.510645,"median":-20.174077,"eighty":-16.884826,"marketCap":99894356},{"date":"2026-07-31","current":-15.715314,"twenty":-32.46514,"median":-20.022763,"eighty":-16.813445,"marketCap":101788088},{"date":"2026-08-07","current":-16.226975,"twenty":-32.288502,"median":-19.406585,"eighty":-16.664276,"marketCap":105102119},{"date":"2026-08-14","current":-18.273621,"twenty":-31.997409,"median":-19.285083,"eighty":-16.519353,"marketCap":118358242},{"date":"2026-08-21","current":-15.574598,"twenty":-31.888849,"median":-18.858377,"eighty":-16.490115,"marketCap":106670425}],"updateTime":1787576654713},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLYX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1113006468","title":"H.C. Wainwright首次覆蓋Polaryx Therapeutics，給予買入評級，目標價7美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113006468","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113006468?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 18:02","pubTimestamp":1783591336,"startTime":"0","endTime":"0","summary":"投资机构H.C. Wainwright今日宣布，对生物制药公司Polaryx Therapeutics Inc.启动首次覆盖研究。该机构给予Polaryx Therapeutics股票“买入”评级，并设定了7美元的目标价。此举意味着分析师看好该公司的发展前景与潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131948077","title":"Polaryx Therapeutics完成1000萬美元私募股權融資，以支持啓動Soteria二期籃子試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1131948077","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131948077?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 20:31","pubTimestamp":1779971476,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics宣布，已完成一笔1000万美元的私募股权融资。此次融资所获资金将专项用于支持其核心候选药物Soteria二期篮子试验的启动工作。\n这笔资金的注入为Polaryx推进其临床开发计划提供了关键的财务支持。二期篮子试验旨在评估Soteria在多种适应症中的疗效与安全性，标志着该药物研发进程中的一个重要里程碑。\n公司表示，此次融资的成功完成，反映了投资者对其研发管线与战略方向的信心。Polaryx计划利用这笔资金加速Soteria的临床开发，以期早日为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629803475","title":"BUZZ-美國食品和藥物管理局授予罕見病藥物快速通道資格後，Polaryx 股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2629803475","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629803475?lang=zh_tw&edition=fundamental","pubTime":"2026-04-21 21:12","pubTimestamp":1776777154,"startTime":"0","endTime":"0","summary":"BUZZ-美国食品和药物管理局授予罕见病药物快速通道资格后，Polaryx 股价上涨4月21日 - ** 药物开发商 Polaryx Therapeutics PLYX.O 股价盘前上涨 4.76% 至 5.97 美元** 公司表示，美国食品和药物管理局已授予其实验性药物PLX-200 \"快速通道 \"资格，用于治疗CLN3病、Krabbe病和Sandhoff病这三种损害神经系统的罕见遗传性疾病。** 美国食品和药物管理局的 \"快速通道 \"标签旨在加快未满足医疗需求的严重疾病治疗方法的开发和审查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nL4T4141AW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119054078","title":"Polaryx Therapeutics四款適應症均獲美國FDA快速通道資格，將納入Soteria籃子試驗評估","url":"https://stock-news.laohu8.com/highlight/detail?id=1119054078","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119054078?lang=zh_tw&edition=fundamental","pubTime":"2026-04-21 20:32","pubTimestamp":1776774724,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics Inc宣布，其针对Soteria篮子试验计划评估的全部四种适应症，均已获得美国食品药品监督管理局授予的快速通道资格。获得FDA快速通道资格，意味着Polaryx的在研药物将有资格享受更频繁的FDA沟通、滚动审评以及优先审评等利好政策。Soteria篮子试验设计旨在高效评估单一疗法对多种相关适应症的疗效。此次四款适应症同时获批快速通道资格，进一步验证了Polaryx科研平台的技术优势及其创新疗法的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194971558","title":"Polaryx Therapeutics獲FDA快速通道資格，Plx-200治療晚嬰期神經元蠟樣脂褐質沉積症（CLN2病）","url":"https://stock-news.laohu8.com/highlight/detail?id=1194971558","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194971558?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 20:33","pubTimestamp":1773750788,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics公司宣布，其研发的药物Plx-200已获得美国食品药品监督管理局（FDA）授予的快速通道资格，用于治疗晚婴期神经元蜡样脂褐质沉积症（CLN2病）。这一资格将加速该药物的研发和审评进程，为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139785167","title":"Polaryx Therapeutics獲FDA安全許可函，將於2026年第三季度啓動Soteria試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1139785167","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139785167?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 20:31","pubTimestamp":1773750679,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics, Inc. 宣布，在获得美国食品药品监督管理局（FDA）的\"安全进行\"许可函后，公司计划于2026年第三季度正式启动Soteria临床试验。\n这一进展标志着Polaryx Therapeutics在药物研发道路上迈出关键一步。FDA的许可函确认了试验方案的安全性，为Soteria试验的开展扫清了监管障碍。公司预计，该试验将为其在研疗法提供重要临床数据支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}